KYNAM CAPITAL MANAGEMENT LP
Q4 2025 Form 13-F
PRINCETON, NEW JERSEY
CIK 0001907884
· CRD 314368
· SEC-registered investment adviser
$1.6B Reported Value Total
KYNAM CAPITAL MANAGEMENT, LP reports 3 total accounts under management (AUM). There are 3 discretionary accounts valued at $2,405,442,793, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered
Discretionary Manager
Private funds (Form ADV)
1 fund
· $2.4B gross asset value
Hedge Fund: $2.4B
Source: Form ADV filed 2026-04-10
Reported value
$1.6B
Quarter over quarter
+45.7%
Holdings
35
Top-10 concentration
71.9%
Key People
Form ADV owners & control persons
Yue "nmn" Tang
LIMITED PARTNER
Jared Joseph Keller
CHIEF OPERATING OFFICER, CHIEF COMPLIANCE OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q4 2025 13F record
Q4 2025 13F filing summary
| Period of report | December 31, 2025 |
|---|---|
| Filed | February 17, 2026 |
| Form | 13F-HR |
| Reported value | $1.6B |
| Positions | 35 |
| Change in reported value | +16.6% |
| New positions | 5 |
| Exited positions | 5 |
| Position turnover | 25.0% |
| Top-10 concentration | 71.9% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 16, 2026
|
34 | $1.8B |
|
Q2 2026 13F
Filed Aug 14, 2026
|
32 | $1.8B |
|
Q1 2026 13F
Filed May 15, 2026
|
36 | $1.6B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
35 | $1.6B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
35 | $1.3B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
31 | $928.8M |
|
Q1 2025 13F
Filed May 15, 2025
|
31 | $1.2B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
29 | $1.7B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
24 | $1.3B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
22 | $1.3B |
|
Q1 2024 13F
Filed May 15, 2024
|
21 | $955.5M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
23 | $902.6M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
27 | $611.4M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
23 | $727.1M |
|
Q1 2023 13F
Filed May 15, 2023
|
34 | $774.6M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
31 | $651.9M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
33 | $474.6M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
31 | $391.6M |
|
Q1 2022 13F
Filed May 13, 2022
|
31 | $308.3M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
30 | $187.1M |
Top 20 holdings · Q4 2025
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | COGT COGENT BIOSCIENCES INC | $219.0M | 13.99% |
| 2 | VERA VERA THERAPEUTICS INC | $173.8M | 11.11% |
| 3 | SNDX SYNDAX PHARMACEUTICALS INC | $169.2M | 10.81% |
| 4 | CLDX CELLDEX THERAPEUTICS INC NEW | $161.4M | 10.31% |
| 5 | PCVX VAXCYTE INC | $134.8M | 8.61% |
| 6 | BCRX BIOCRYST PHARMACEUTICALS INC | $73.1M | 4.67% |
| 7 | BEAM BEAM THERAPEUTICS INC | $67.6M | 4.32% |
| 8 | VRDN VIRIDIAN THERAPEUTICS INC | $45.8M | 2.92% |
| 9 | TYRA TYRA BIOSCIENCES INC | $41.1M | 2.63% |
| 10 | CGON CG ONCOLOGY INC | $39.3M | 2.51% |
| 11 | CTMX CYTOMX THERAPEUTICS INC | $38.2M | 2.44% |
| 12 | NRIX NURIX THERAPEUTICS INC | $37.4M | 2.39% |
| 13 | WVE WAVE LIFE SCIENCES LTD | $36.9M | 2.36% |
| 14 | CGEM CULLINAN THERAPEUTICS INC | $32.2M | 2.06% |
| 15 | IMCR IMMUNOCORE HLDGS PLC | $29.7M | 1.9% |
| 16 | MBX MBX BIOSCIENCES INC | $29.5M | 1.88% |
| 17 | KALV KALVISTA PHARMACEUTICALS INC | $29.2M | 1.87% |
| 18 | BEAM C BEAM THERAPEUTICS INC | $26.0M | 1.66% |
| 19 | APLS APELLIS PHARMACEUTICALS INC | $22.8M | 1.46% |
| 20 | DVAX DYNAVAX TECHNOLOGIES CORP | $21.2M | 1.35% |
Values as reported on the Q4 2025 Form 13F. Every position is in the holdings table below.